SPRY Stock Forecast 2025-2026
Distance to SPRY Price Targets
SPRY Price Momentum
10 Quality Stocks Worth Considering Now
Researching ARS Pharma (SPRY) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on SPRY and similar high-potential opportunities.
Latest SPRY Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, SPRY has a bullish consensus with a median price target of $30.00 (ranging from $19.00 to $40.00). The overall analyst rating is Strong Buy (9.7/10). Currently trading at $12.60, the median forecast implies a 138.1% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Andreas Argyrides at Wedbush, suggesting a 50.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SPRY Analyst Ratings
SPRY Price Target Range
Latest SPRY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SPRY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 7, 2025 | Scotiabank | Louise Chen | Sector Outperform | Initiates | $30.00 |
| Jan 14, 2025 | Raymond James | Ryan Deschner | Strong Buy | Maintains | $28.00 |
| Jan 13, 2025 | Leerink Partners | Roanna Ruiz | Outperform | Maintains | $27.00 |
| Oct 8, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Reiterates | $30.00 |
| Sep 20, 2024 | Leerink Partners | Roanna Ruiz | Outperform | Maintains | $25.00 |
| Sep 16, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Reiterates | $30.00 |
| Sep 9, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Reiterates | $30.00 |
| Aug 20, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Initiates | $30.00 |
| Aug 13, 2024 | Raymond James | Ryan Deschner | Strong Buy | Upgrade | $22.00 |
| Jul 25, 2024 | Raymond James | Ryan Deschner | Outperform | Initiates | $18.00 |
| Mar 11, 2024 | Wedbush | Andreas Argyrides | Outperform | Reiterates | $19.00 |
| Mar 5, 2024 | Leerink Partners | Roanna Ruiz | Outperform | Upgrade | $18.00 |
| Nov 13, 2023 | Wedbush | Andreas Argyrides | Outperform | Maintains | $13.00 |
| Sep 21, 2023 | Wedbush | Andreas Argyrides | Outperform | Maintains | $5.00 |
| Sep 20, 2023 | William Blair | Tim Lugo | Market Perform | Downgrade | $0.00 |
| Aug 14, 2023 | Wedbush | Outperform | Reiterates | $0.00 | |
| Jun 21, 2023 | Wedbush | Andreas Argyrides | Outperform | Maintains | $15.00 |
| May 18, 2023 | Wedbush | Andreas Argyrides | Outperform | Reiterates | $17.00 |
| May 12, 2023 | Wedbush | Andreas Argyrides | Outperform | Reiterates | $17.00 |
| May 10, 2023 | Wedbush | Andreas Argyrides | Outperform | Reiterates | $17.00 |
Ars Pharmaceuticals Inc (SPRY) Competitors
The following stocks are similar to ARS Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Ars Pharmaceuticals Inc (SPRY) Financial Data
Ars Pharmaceuticals Inc has a market capitalization of $1.29B with a P/E ratio of 157.5x. The company generates $89.15M in trailing twelve-month revenue with a 9.0% profit margin.
Revenue growth is +4,086.7% quarter-over-quarter, while maintaining an operating margin of +54.5% and return on equity of +3.3%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Ars Pharmaceuticals Inc (SPRY) Business Model
About Ars Pharmaceuticals Inc
Develops self-administered therapeutics for allergies.
The company focuses on creating innovative biopharmaceutical products that allow patients to self-administer treatments for allergy-related conditions. By providing user-friendly delivery mechanisms, Ars Pharmaceuticals generates revenue through the development and commercialization of these therapeutics, aimed at improving patient safety and convenience during emergency situations.
Ars Pharmaceuticals is dedicated to addressing critical healthcare needs and enhancing treatment options for allergic reactions. Its commitment to transforming therapeutic landscapes highlights its potential for growth in the biopharmaceutical sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
155
CEO
Mr. Richard Lowenthal M.B.A., M.S., MSMSEL
Country
United States
IPO Year
2020
Website
ars-pharma.comArs Pharmaceuticals Inc (SPRY) Latest News & Analysis
ARS Pharmaceuticals shares surged after the company reported unexpected fourth-quarter metrics, successfully retaking its 50-day moving average in a bullish post-earnings response.
ARS Pharmaceuticals' unexpected fourth-quarter metrics and strong post-earnings performance can signal growth potential, attracting investor interest and potentially driving share prices higher.
ARS Pharmaceuticals will hold a Q4 2024 earnings call on March 20, 2025, at 8:30 AM ET, featuring key executives and analysts from various financial firms.
ARS Pharmaceuticals' earnings call signals potential insights into financial performance and future strategies, crucial for assessing investment viability and market outlook.
ARS Pharmaceuticals' stock rose 25% after strong Q4 and full-year 2024 earnings, driven by the needle-free epinephrine treatment, neffy, targeting a $3 billion market. Risks include competition and pricing pressures.
ARS Pharmaceuticals' stock surge reflects investor optimism over strong earnings and neffy's market potential, but risks from competition and dependency on a single product warrant caution.
Neffy® (epinephrine nasal spray) generated $7.3 million in U.S. net product revenue since its late September 2024 launch.
The $7.3 million revenue from neffy® indicates strong market demand and potential growth, positively impacting the company's financial outlook and stock performance.
ARS Pharmaceuticals, Inc. (SPRY) reported Q3 earnings of $0.52 per share, surpassing expectations of a $0.04 loss and improving from a $0.07 loss per share a year prior.
ARS Pharmaceuticals' earnings beat expectations, signaling strong performance and potential growth, which can boost investor confidence and drive stock prices higher.
Neffy 1 mg is the first and only needle-free epinephrine treatment approved for younger children, marking a significant advancement in pediatric allergy care.
The approval of Neffy 1 mg as a needle-free epinephrine treatment for young children opens new market opportunities, potentially increasing sales and attracting investor interest in the pharmaceutical sector.
Frequently Asked Questions About SPRY Stock
What is Ars Pharmaceuticals Inc's (SPRY) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Ars Pharmaceuticals Inc (SPRY) has a median price target of $30.00. The highest price target is $40.00 and the lowest is $19.00.
Is SPRY stock a good investment in 2025?
According to current analyst ratings, SPRY has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $12.60. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SPRY stock?
Wall Street analysts predict SPRY stock could reach $30.00 in the next 12 months. This represents a 138.1% increase from the current price of $12.60. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Ars Pharmaceuticals Inc's business model?
The company focuses on creating innovative biopharmaceutical products that allow patients to self-administer treatments for allergy-related conditions. By providing user-friendly delivery mechanisms, Ars Pharmaceuticals generates revenue through the development and commercialization of these therapeutics, aimed at improving patient safety and convenience during emergency situations.
What is the highest forecasted price for SPRY Ars Pharmaceuticals Inc?
The highest price target for SPRY is $40.00 from at , which represents a 217.5% increase from the current price of $12.60.
What is the lowest forecasted price for SPRY Ars Pharmaceuticals Inc?
The lowest price target for SPRY is $19.00 from Andreas Argyrides at Wedbush, which represents a 50.8% increase from the current price of $12.60.
What is the overall SPRY consensus from analysts for Ars Pharmaceuticals Inc?
The overall analyst consensus for SPRY is bullish. Out of 7 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $30.00.
How accurate are SPRY stock price projections?
Stock price projections, including those for Ars Pharmaceuticals Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
